全脑放疗联合补充精确放疗在肺癌脑转移患者中的应用

The effect of whole brain radiotherapy combined with supplement precise radiotherapy for lung cancer patients with brain metastasis

目的探讨全脑放疗联合补充精确放疗在肺癌脑转移患者中的应用效果。方法选取2017年1月至2019年1月于浙江省肿瘤医院就诊的肺癌脑转移患者40例,按随机数字表法分为两组,每组20例,对照组给予单纯的全脑放疗,观察组在此基础上给予精确放疗,对比两组患者的放疗效果。结果观察组患者的治疗有效率、疾病控制率均高于对照组(15/20比7/20、 19/20比11/20),差异有统计学意义(χ^(2) = 8.02、6.67,P<0.05);观察组治疗后健康调查简表评分高于对照组;两组不良反应发生率均为6/20。观察组无进展生存时间为(26.5 ± 2.6)个月,显著高于对照组的(5.6 ± 1.2)个月,差异有统计学意义(P = 0.002);观察组治疗后4年总生存率为77.8%,显著高于对照组的23.2%(P<0.01)。结论肺癌脑转移患者在全脑放疗的基础上给予补充精确放疗,能明显提高治疗效果,提高患者存活率,改善预后。

Objective To explore the effect of whole brain radiotherapy combined with complementary precise radiotherapy in patients with brain metastases from lung cancer.Methods A total of 40 patients with brain metastases from lung cancer treated in Zhejiang Cancer Hospital from January 2017 to January 2019 were randomly divided into two groups,each group with 20 patients.The control group was given pure whole brain radiotherapy,and the observation group was given complementary precise radiotherapy on the basis of control group.The radiotherapy effects of the two groups were compared.Results The effective rate and disease control rate of the observation group were higher than those in the control group(15/20 vs.7/20,19/20 vs.11/20),there were significantly differences(χ^(2)=8.02 and 6.67,P<0.05).After treatment,the scoresof SF-36 in the observation group were higher than those in the control group(P<0.05).The incidence of adverse reactions in the two groups was 6/20.The progressionfree survival(PFS)time in the observation group was significantly higher than that in the control group:(26.5±2.6)months vs.(5.6±1.2)months,P=0.002.The average overall survival rate in the observation group was significantly higher than that in the control group(77.8%vs.23.2%,P<0.01).Conclusions Whole brain radiotherapy combined with supplement precise radiotherapy for lung cancer patients with brain metastasiscan significantly improve the treatment effect and survival rate,and improve the prognosis.